Editorial

Abstract

Cardiovascular disease remains the leading cause of morbidity and mortality in individuals with both type 1 and type 2 diabetes. Among the major modifiable risk factors, dyslipidaemia plays a critical role in cardiovascular risk. The landmark Steno-2 Study demonstrated that multifactorial intervention—addressing glycaemic control, blood pressure, and lipid levels—is essential in reducing cardiovascular events in people with diabetes. Despite this evidence, the majority of patients fail to achieve recommended targets for glycaemic, lipid, and blood pressure control in clinical practice.